MARKET INSIGHTS

The United States Xylooligosaccharides (XOS) market size was valued at USD 23.7 million in 2024. The market is projected to grow from USD 26.1 million in 2025 to USD 48.9 million by 2032, exhibiting a CAGR of 9.4% during the forecast period.

Xylooligosaccharides are prebiotic compounds derived from xylan‑rich plant materials, primarily used as functional food ingredients to support digestive health by selectively stimulating beneficial gut bacteria. These oligosaccharides are classified into different purity grades including XOS‑95P, XOS‑70P, XOS‑70L, XOS‑35P, and XOS‑20P, with applications spanning functional foods (accounting for 68% of 2023 consumption), dietary supplements, and animal nutrition.

Market growth is being driven by rising consumer awareness of gut microbiome health, with probiotic and prebiotic product demand increasing 22% year‑over‑year in 2023. The segment’s expansion is further supported by clean‑label food trends and clinical evidence demonstrating XOS benefits for metabolic and immune health. Major producers are investing in sustainable production methods, with 40% of 2024 capacity utilizing agricultural byproducts. Recent industry developments include DuPont’s 2024 expansion of its XOS production facility in Iowa to meet growing demand for synbiotic formulations.

United States Xylooligosaccharides (XOS) Market – View in Detailed Research Report

United States Xylooligosaccharides (XOS) Market

The United States Xylooligosaccharides (XOS) market size was valued at USD 23.7 million in 2024 and is projected to reach USD 42.5 million by 2030, at a CAGR of 10.2% during the forecast period 2024‑2030.

MARKET DYNAMICS

MARKET DRIVERS

Growing Consumer Awareness About Gut Health Boosts XOS Adoption

The increasing consumer focus on digestive health and microbiome balance is creating significant demand for prebiotic ingredients like xylooligosaccharides. With over 70 million Americans suffering from digestive disorders annually, functional food manufacturers are incorporating XOS at record levels. The prebiotic supplement market grew by 18% in 2023 alone, with XOS formulations capturing 22% of new product launches.

Expansion in Functional Food Applications Drives Market Growth

XOS adoption in functional foods is accelerating across multiple categories, particularly in dairy and bakery products where its stability under processing conditions provides formulation advantages. The dairy sector accounted for 38% of total XOS usage in 2023, with yogurt applications growing at 27% year‑over‑year.

MARKET RESTRAINTS

High Production Costs Limit Widespread Adoption

While demand grows, xylooligosaccharides face challenges from relatively high production costs compared to conventional prebiotics. The enzymatic hydrolysis process required for XOS production remains capital‑intensive, with current manufacturing costs approximately 40‑50% higher than inulin or FOS production.

MARKET CHALLENGES

Regulatory Complexities Surrounding Health Claims

Manufacturers face ongoing challenges navigating the complex regulatory environment for prebiotic health claims. While the FDA recognizes XOS as Generally Recognized As Safe (GRAS), obtaining approval for specific gut health claims requires extensive clinical validation.

MARKET OPPORTUNITIES

Emerging Pet Nutrition Sector Presents Significant Growth Potential

The pet nutrition market represents a high‑growth opportunity for XOS suppliers, with the segment expanding at 22% annually. Pet food manufacturers are increasingly incorporating prebiotics to address growing concerns about pet digestive health.

Sustainable Production Methods Open New Market Possibilities

Innovations in sustainable XOS production from agricultural byproducts present significant opportunities for cost reduction and market expansion. Recent advances enable extraction from corn cobs, rice husks, and sugarcane bagasse, reducing production costs by 30‑35% while appealing to environmentally conscious consumers.

---

Top 10 Companies in the United States Xylooligosaccharides (XOS) Market (2026)

10️⃣ 1. AIDP, Inc.

Headquarters: Irvine, California, USA
Key Offering: XOS‑95P, XOS‑70P, XOS‑70L, XOS‑35P, XOS‑20P for functional foods, dietary supplements, and animal nutrition

AIDP, Inc. has emerged as a market leader, commanding approximately 18% of total U.S. XOS revenues in 2024 through its proprietary prebiotic formulations and strong distribution partnerships with major food manufacturers.

Sustainability & Growth Initiatives:

• Invested USD 12 million in its California production facility to expand capacity and improve yield.
• Adopted green chemistry processes, using 40% agricultural byproducts.
• Developed a proprietary enzyme blend that reduces production costs by 25%.

---

9️⃣ 2. DuPont Nutrition & Health (now part of IFF)

Headquarters: Wilmington, Delaware, USA
Key Offering: HOWARU prebiotic line for dairy, bakery, and supplement applications

DuPont Nutrition & Health maintains a strong position with its HOWARU prebiotic line, leveraging its extensive dairy industry network and capturing 22% of the U.S. XOS market for functional dairy applications in 2024.

Sustainability & Growth Initiatives:

• Expanded Iowa facility to support synbiotic formulations.
• Committed to 100% renewable energy for all U.S. manufacturing plants by 2030.
• Invested in R&D for high‑purity XOS‑95P to meet pharmaceutical demand.

---

8️⃣ 3. Stratum Nutrition

Headquarters: San Diego, California, USA
Key Offering: Custom XOS blends for functional foods and dietary supplements

Stratum Nutrition focuses on innovative blends tailored to specific product categories, enabling lower dosage levels while maintaining efficacy.

Sustainability & Growth Initiatives:

• Partnered with local farms to source xylan‑rich byproducts.
• Launched a zero‑waste production line in 2025.
• Invested in AI‑driven process optimization.

---

7️⃣ 4. Parchem Fine & Specialty Chemicals

Headquarters: Charlotte, North Carolina, USA
Key Offering: High‑purity XOS for pharmaceutical and nutraceutical applications

Parchem Fine & Specialty Chemicals supplies XOS‑95P to pharmaceutical companies and nutraceutical brands, focusing on purity and consistency.

Sustainability & Growth Initiatives:

• Implemented closed‑loop water recycling in 2024.
• Reduced CO₂ emissions by 18% through process optimization.
• Expanded capacity to 1.5 million kg/year.

---

6️⃣ 5. BENEO GmbH

Headquarters: Berlin, Germany (U.S. operations headquartered in Chicago, Illinois)
Key Offering: Organic and sustainable XOS blends for dietary supplements and functional foods

BENEO GmbH has been expanding its presence through technical collaborations with supplement manufacturers, resulting in a 40% increase in its U.S. XOS sales between 2022‑2024.

Sustainability & Growth Initiatives:

• Adopted 100% certified organic raw materials.
• Invested in renewable energy for U.S. plants.
• Launched a sustainability certification program for suppliers.

---

5️⃣ 6. NxTerra Specialty Ingredients

Headquarters: Madison, Wisconsin, USA
Key Offering: Sustainable XOS from corn cobs and rice husks for pet nutrition and functional foods

NxTerra Specialty Ingredients differentiates itself with organic and sustainable XOS variants, capturing 8% market share since 2021.

Sustainability & Growth Initiatives:

• Utilizes 60% agricultural byproducts in production.
• Developed a proprietary extraction process that cuts costs by 30%.
• Partnered with local farmers for raw material sourcing.

---

4️⃣ 7. Nutralliance

Headquarters: Portland, Oregon, USA
Key Offering: XOS blends for functional beverages and snack foods

Nutralliance focuses on high‑value applications in beverages, leveraging its strong distribution network.

Sustainability & Growth Initiatives:

• Committed to 100% recyclable packaging.
• Invested in R&D for low‑temperature processing.
• Partnered with universities for clinical trials.

---

3️⃣ 8. DFA Ingredients

Headquarters: Houston, Texas, USA
Key Offering: XOS for pet nutrition and functional foods

DFA Ingredients supplies XOS to pet food manufacturers, capitalizing on the growing pet nutrition segment.

Sustainability & Growth Initiatives:

• Developed a low‑energy extraction process.
• Implemented a carbon‑neutral supply chain by 2028.
• Invested in community outreach programs.

---

2️⃣ 9. ABF Ingredients

Headquarters: London, United Kingdom (U.S. operations in New York, NY)
Key Offering: High‑purity XOS for pharmaceutical and nutraceutical applications

ABF Ingredients serves the U.S. market with high‑purity XOS for pharmaceutical and nutraceutical brands.

Sustainability & Growth Initiatives:

• Adopted renewable energy sources across plants.
• Reduced waste by 25% through process improvements.
• Launched a supplier sustainability assessment program.

---

1️⃣ 10. XYLERA

Headquarters: New York, New York, USA
Key Offering: Organic XOS blends for functional foods and dietary supplements

XYLERA specializes in organic XOS, targeting health‑conscious consumers and premium brands.

Sustainability & Growth Initiatives:

• All XOS blends certified organic and non‑GMO.
• Invested in renewable energy for all U.S. facilities.
• Developed a closed‑loop waste management system.

---

Download FREE Sample Report

Get Full Report

Outlook

The United States XOS market is projected to grow from USD 26.1 million in 2025 to USD 48.9 million by 2032, with a CAGR of 9.4%. The forecast for 2034 indicates a market size of approximately USD 60 million, reflecting continued momentum driven by gut health awareness and clean‑label demand.

Future Trends

• Synbiotic Formulations: Combining XOS with probiotic strains is expected to grow at 12‑15% annually through 2032.
• Pet Nutrition: The pet nutrition segment is projected to grow at 22% annually, driven by premiumization and functional ingredient demand.
• Sustainable Production: Use of agricultural byproducts is projected to rise to 50% of total production capacity by 2030, reducing costs and enhancing brand appeal.
• Regulatory Landscape: Ongoing FDA claim approvals will accelerate product launches, but companies must invest in clinical validation.
• High‑Purity XOS‑95P: Demand for pharmaceutical‑grade XOS is expected to increase, driven by clinical evidence supporting metabolic and immune benefits.